3 Dividend Stocks Paying Over 6.6% That Are Worth a Closer Look

Annaly yields 13.2% and runs a ~ $105B investment portfolio on $16.1B of equity (high leverage); it earned $0.74/share last quarter vs a $0.70 quarterly dividend (payout covered) but remains exposed to downside in stressed markets. Healthpeak yields 7.3% (monthly), completed the Janus Living IPO raising $878M and bought the 1.4M sq ft Gateway Crossing lab campus for $600M to shift capital into outpatient/lab development to bolster cash flow. Vici yields 6.6% and has grown dividends at a 6.6% CAGR since late 2018; recent deals include a $144M Canada hotels/casinos purchase and a $1.5B loan tied to One Beverly Hills, supporting continued dividend growth.

Analysis

Healthcare- and lab-oriented landlords (Healthpeak exposure) are indirect beneficiaries of continued capex in AI and bioanalytics: higher datacenter and lab buildouts lift demand for specialized wet-lab and chilled-space footprints, which should compress leasing lead times and support rents at the margin. Conversely, mortgage-REITs (Annaly-style exposure) remain a carry-dependent trade whose economics invert quickly if short-term funding costs spike or MBS convexity turns against them; the next 3–9 months are the highest-probability window for volatility as macro data re-prices front-end rates. Vici-style triple-net portfolios enjoy a structural inflation hedge via escalators, but they are second-order exposed to leisure demand elasticity — a 10–15% decline in regional gaming visitation would show up as incremental credit stress on smaller tenants and slow inorganic growth opportunities over 6–18 months. Market-structure knock-on: a more volatile rate regime increases flow into securitization and hedging products, boosting exchange/clearing volumes (benefit to market infra names) while increasing repo and CP funding premia for levered REITs.

Key Decisions for Investors

• Long VICI (12 months): accumulate on any sub-10% intraday pullback; target 12–18% total return driven by rent escalators and selective loan-to-own optionality. Size: 2–4% NAV. Hedge: buy 6–9 month 7–10% OTM puts (insurance cost ~small premium) to cap downside in a leisure-demand shock.
• Relative-value pair — Long DOC / Short NLY (6–12 months): overweight operating REIT with asset growth optionality versus rate-sensitive mortgage-REIT. Notional: 1:1 to neutralize broad equity beta; rationale is capture spread compression if lab/outpatient fundamentals re-rate while limiting macro rate exposure that would hit both equally.
• Tactical hedge or asymmetric short on NLY (3–6 months): buy near-term 10–15% OTM puts (or payer swaptions with short tenor) to express downside if front-end rates spike or MBS basis widens. Reward: protects carry positions with limited premium outlay; tail risk: rapid convexity losses if volatility collapses.
• Macro overlay — increase allocation to market-infra/clearing exposure (NDAQ) for 6–12 months to capture higher hedging/securitization volumes if rate volatility persists. Size: modest (1–2% NAV) as a diversifier against REIT funding stress; exit trigger: 20% drop in volume or Fed pivot.